Deadline looms for EU product info update – and there's more on the way
This article was originally published in Scrip
Companies marketing pharmaceuticals in the EU have received a gentle reminder from the European Medicines Agency that all their product information must be brought up to date by the end of this month, regardless of the route the products took to gain marketing authorization.
You may also be interested in...
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.